BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Gruenenthal GmbH And Ingenium Pharmaceuticals Enter INGENOtyping(TM) Agreement


10/19/2005 5:10:09 PM

MUNICH and AACHEN, Germany, Feb. 25 /PRNewswire/ -- Ingenium Pharmaceuticals AG and Gruenenthal GmBH announced today a collaboration in which Ingenium will use its INGENOtyping(TM) technology platform to develop animal models with defined gene alterations. The focus of the collaboration will be the development of unique animal models for genes relating to novel therapeutic discoveries in Gruenenthal's major therapeutic focus area of pain. No financial terms were disclosed.

"Gruenenthal is an established leader in pain research and Ingenium is pleased to collaborate with them to meet their research and development goals," stated Michael Nehls, M.D., Ph.D., Chief Executive at Ingenium. "Our results to date for producing models, both for our internal research and for our partners, demonstrate the power and speed of the technology, and we continue to prove that INGENOtyping(TM) can provide a mouse model of choice in an unprecedented time frame of only a few months. Drug discovery is a long process where every day invested has an impact on the bottom line. The time- savings of the INGENOtyping(TM) platform are therefore significant in comparison to other technologies."

"We are looking forward to the opportunity to employ Ingenium's unique technology for the rapid generation of mouse models," commented Klaus Langner, Ph.D., Head of Research at Gruenenthal. "We hope that INGENOtyping(TM) will allow us to validate a couple of very promising novel targets for the treatment of pain that we have identified in the course of our five year molecular pain project sponsored in part by the German Ministry for Education and Research (BMBF)."

Ingenium's INGENOtyping(TM) technology is a high-speed second-generation tool for the in vivo validation of drug targets. INGENOtyping(TM) can provide in as little as four months a series of mammalian models that carry unique genetic alterations in any target gene of interest. These models include knockouts as well as more subtle functional alterations, such as increased and reduced gene target activity. The INGENOtyping(TM) technology is based on a genetically subtle chemical process that generates point mutations in genes and Ingenium's expertise in quickly and reliably producing and analyzing mammalian models of disease.

Gruenenthal is a family-owned, expansive, innovative and cooperative company based in Aachen, Germany. Gruenenthal's Research & Development is focused on pain. Efforts for this indication are supported by basic research reaching as far back as the identification of potential new targets. Other therapeutic fields of strategic interest are gynaecology and antiinfectives. Gruenenthal's main markets are Europe, Latin America and China.

The basis of Ingenium's business is its knowledge and expertise in generating the biological information critical to the discovery, validation and development of therapeutics. Ingenium's biology-based target discovery technology, Deductive Genomics(R), involves a functional genomics analysis of an entire mammalian genome to locate novel therapeutic entry points to treat disease. From the breadth of knowledge generated by Deductive Genomics(R), Ingenium is currently advancing a pipeline of novel models and biologically validated drug targets in the areas of inflammatory bowel disease, neurodegeneration and obesity/diabetes. Ingenium has research partnership agreements with Bayer AG, Elan Corporation, F. Hoffmann-La Roche Ltd., Sequenom Inc., Oxagen Ltd. and Wyeth, in addition to numerous international academic collaborations. The company benefits from funding from premier investors, an experienced management team, top industry advisors and a growing patent portfolio.

For more information contact: For Ingenium: Gretchen L.P. Schweitzer Vice President Ingenium Pharmaceuticals AG Ph: 49 (89) 8565-2398 gretchen.schweitzer@ingenium-ag.com For Gruenenthal: Erik J. Wade, Ph.D. Research Alliances Gruenenthal GmbH Ph: 49 (241) 569-2733 erik.wade@grunenthal.de

Ingenium Pharmaceuticals AG

CONTACT: Gretchen L.P. Schweitzer, Vice President, IngeniumPharmaceuticals AG, +49 (89) 8565-2398, gretchen.schweitzer@ingenium-ag.com;or Erik J. Wade, Ph.D., Research Alliances, Gruenenthal GmbH, +49 (241) 569-2733, erik.wade@grunenthal.de



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES